Ten post jest także dostępny w języku: polski
Another company has announced success in clinical trials. This is about a product developed by Moderna. The vaccine in the third phase of clinical trials showed 94.5% effectiveness. The company wants to apply for an accelerated market authorisation.
Scientific battle for victory with COVID-19
The race for the groundbreaking discovery of an effective preparation for COVID-19 continues. According to the World Health Organization (WHO), 46 preparations are currently undergoing clinical trials around the world, 10 of which are in the last (third) stage of research. These projects include Pfizer and BioNTech, which were the first to publish the preliminary results of their research, and Moderna. The third phase research is also being conducted in several Chinese projects and a preparation developed by the British-Swedish concern AstraZeneca and Oxford University, about which we wrote more here.
Furthermore, the list published by the WHO on 12 November 2020 also includes 164 candidates for the COVID-19 vaccine in the preclinical evaluation.
Moderna vaccine even more effective?
Moderna announced yesterday that a preliminary analysis of the company’s third phase clinical trials of COVID-19 vaccine candidate suggests an essentially consistent safety and efficacy profile across all subgroups evaluated. In total, the efficacy of the preparation was estimated at 94.5%. This is an even better result than the recently described results of Pfizer and BioNTech! Based on these data, Moderna intends to submit an application to the FDA (U.S. Food and Drug Administration) for emergency approval. The company also plans to apply to global regulatory agencies for authorization.
If the preparation is placed on the market, Moderna will deliver approximately 20 million doses of mRNA-1273 in the US by the end of 2020. Moreover, it has been reported that in 2021, the company may deliver between 500 million and 1 billion doses of COVID-19 vaccine worldwide.